Allogene Therapeutics, Inc. beat EPS estimates 100% of the time across 3 reported quarters (3 beats, 0 misses). Data sourced from SEC EDGAR.
| Quarter | EPS Estimate | EPS Actual | Surprise | Result |
|---|---|---|---|---|
| Q22026 FY2026 | $-0.16 | $-0.13 | +18.8% | Beat |
| Q12026 FY2026 | $-0.19 | $-0.18 | +5.3% | Beat |
| Q42025 FY2025 | $-0.25 | $-0.17 | +32.0% | Beat |
Back to ALLO overview · ALLO holders · ALLO KPIs
Data sourced from U.S. SEC EDGAR filings. Not personalized investment advice.